(Reuters) – British drugmaker GSK Plc said on Friday the U.S. Food and Drug Administration had approved its experimental drug to treat anemic patients with a type of bone marrow cancer called myelofibrosis.
(Reporting by Mariam Sunny in Bengaluru; Editing by Devika Syamnath)
